TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00434837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial graft tension during ACL reconstruction surgery
Description: The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial graft tension during ACL reconstruction surgery
Description: The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown.
Study: NCT05939518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's Fluid Bolus Response to Low Urinary Output
Description: During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Fluid Bolus Response to Low Urinary Output
Description: During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol
Description: During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol
Description: During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
Study: NCT04016363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual hold
Description: ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
Study: NCT02879136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Patient will be randomized to Methylphenidate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All Patients will have standard of care PT used for PD patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All Patients will have standard of care PT used for PD patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All Patients will have standard of care PT used for PD patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Patient will be randomized to Atomoxetine
Study: NCT04375033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine with naloxone
Description: The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable subcutaneous buprenorphine
Description: Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit through Week 48.
Study: NCT03162965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oraquick HIV Self Test
Description: This is an oral swab in home HIV test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Based HIV Counseling and Testing (HCT)
Description: Receiving Counseling and Testing for HIV at the clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Based HIV Counseling and Testing (HCT)
Description: Receiving Counseling and Testing for HIV at the clinic.
Study: NCT02990338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Study: NCT04369599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V/Q System
Description: With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
Study: NCT03347786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Intra-arterial Verapamil
Description: Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg Intra-arterial Verapamil
Description: Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
Study: NCT02359123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabics capsules
Description: Cannabis extract in an oil formulation
Study: NCT02342171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Patients will be treated with plasma from recovered EVD patients.
Study: NCT00711451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual removal
Description: Manual removal of placenta during cesarean delivery
Study: NCT01885897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
Study: NCT00711451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expressed removal
Description: Surgeon will perform an expressed delivery of the placenta
Study: NCT04205591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: split bone block technique
Description: A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: split bone block technique
Description: A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
Study: NCT00122772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy
Study: NCT01226953

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) vaccine
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
Study: NCT00122772

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy/Cisplatin
Description: External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy/Cisplatin
Description: External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly
Study: NCT00878046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy Silent™ Hip femoral prosthesis
Description: A short cementless, femoral component for use in total hip arthroplasty
Study: NCT06501794

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative measurement of eye movements
Description: Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
Study: NCT04039022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan and bupropion) oral tablets
Description: Oral tablets, taken twice daily for up to 12 months.
Study: NCT03210363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Biological samples
Description: Blood sample
Study: NCT04257838

Intervention type: DRUG
Intervention: Piperacillin/tazobactam or Meropenem
Description: The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.
Study: NCT03126292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety Handout
Description: Handout regarding early child safety
Study: NCT03124303

Intervention type: PROCEDURE
Intervention: High Density-Electroencephalogram
Description: EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium

Intervention type: PROCEDURE
Intervention: High Density-Electroencephalogram
Description: EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: MRI scan of brain

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: MRI scan of brain

Intervention type: PROCEDURE
Intervention: Blood specimen collection
Description: Blood will be collected from participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillometry
Description: A pupillometer is a device that measures the size of the pupils.
Study: NCT02313545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6NVS Cream
Description: IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%
Study: NCT03510260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group I
Description: Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group II
Description: The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
Study: NCT04244760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment for verbal patients
Description: The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment for non-verbal patients
Description: The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
Study: NCT01205035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 2.0mg
Description: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
Study: NCT01225523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel; Cisplatin; 5-Fluorouracil
Description: Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
Study: NCT02948231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral Implant is implanted in the Mitral valve
Study: NCT05552599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: woolen blanket
Description: Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
Study: NCT02549638

Intervention type: GENETIC
Intervention: DNA Extraction
Description: We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
Study: NCT02628145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Intervention
Description: The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
Study: NCT03922399

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser and Surgery
Description: Laser and Surgery in patients with major burn scars Evaluating after three years treatment
Study: NCT03633578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walk test
Description: The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed
Study: NCT02628145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
Study: NCT03000166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-Up Intervention
Description: Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
Study: NCT01460537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 as 30-minutes IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 as 30-minutes IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Description: Infusion of 500 ml of 0.9% NaCl over 30-minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6964 fixed dose
Description: BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
Study: NCT01225523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine
Description: Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
Study: NCT02077907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Super Cereal Plus (SC+)
Study: NCT02303483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01282554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation program (Rehab 400)
Description: electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months.
Study: NCT03689088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldfish
Description: Goldfish will be placed in the eye for 24h monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonometry
Description: Fellow eye will be measured by tonometry
Study: NCT02077907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Cereal (SC), fortified oil, sugar
Study: NCT04150757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal ketamine
Description: Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
Study: NCT03142997

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: we will perform lung ultrasound for both groups to calculate lung score.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: we will perform lung ultrasound for both groups to calculate lung score.
Study: NCT02101606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Description: TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
Study: NCT02175563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback from smartphone based app
Study: NCT02605863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth daily for 12 months
Study: NCT03551418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching a video
Description: Watching a video of an adult with DS washing his hands
Study: NCT02137434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Description: Dietary calcium from skimmed milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementary calcium
Description: Supplementary calcium from calcium carbonate
Study: NCT04681664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: 50 % fat
Study: NCT00004154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules for 25 days of 28 day cycle.